we hypothesize that screening patient populations with low ASNS expression and developing combination therapies that sensitize patients to pegaspargase could break through existing bottlenecks, effectively reverse tumor drug resistance, and significantly advance the application of asparaginase in treating solid tumors. Here, ASPG is linked to neoplasm.